The future of brain-computer interfaces (BCIs) is shifting towards a new frontier: cognitive disorders. While BCIs have made remarkable progress in restoring movement and speech for those with paralysis, the focus is now on tackling the global burden of brain diseases, such as depression, anxiety, and PTSD. The key to this shift lies in understanding the fundamental differences between decoding movement and cognition. Movement is represented in a compact, stable area of the brain, making it easier to decode. In contrast, cognitive processes like attention, memory, and emotion are spread across multiple regions and networks, which reorganize dynamically. This complexity means that the same brain signal can have different meanings in different contexts, presenting a unique challenge for BCI development.
Ignacio Saez, PhD, Director of the Laboratory for Human Neurophysiology at the Icahn School of Medicine, outlines a roadmap for next-generation cognitive BCIs in a recent review published in Trends in Cognitive Sciences. He emphasizes that the field is at a pivotal moment, with advances in intracranial recording, decoding, and clinical neuromodulation making it plausible to build BCIs that target cognitive functions. This shift requires merging BCI research, which has focused on reading the brain, with clinical neuromodulation, which has focused on stimulating it, into a closed-loop system.
The challenge lies in developing systems that can detect dysfunctional brain states and respond with precisely timed, adaptive neurostimulation. While many of the necessary building blocks already exist, such as intracranial brain recording, adaptive neurostimulation, and high-resolution neurochemical sensing, integrating these technologies into intelligent, closed-loop systems is the next major hurdle. This integration could lead to more precise, personalized treatments for serious brain disorders.
The push towards cognitive BCIs is also driven by commercial interest. Companies that have driven progress in motor and speech BCIs are now looking to cognitive applications as the next frontier. The addressable patient populations for cognitive BCIs are far larger than those for paralysis, spanning common psychiatric and neurological conditions. However, translating these advances from the laboratory into approved therapies will require close collaboration among academic researchers, clinicians, and industry to develop the hardware, algorithms, and regulatory pathways necessary for clinical-grade cognitive BCIs.
In summary, the future of BCIs is moving towards cognitive applications, presenting a new set of challenges and opportunities. By understanding the differences between decoding movement and cognition, and by integrating advanced technologies into closed-loop systems, we may unlock more precise and personalized treatments for a wide range of brain disorders.
